Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 step » _ step (Expand Search), a step (Expand Search), 2 step (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 step » _ step (Expand Search), a step (Expand Search), 2 step (Expand Search)
-
16461
-
16462
-
16463
-
16464
DdataSheet_1_Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report.pdf
Published 2021“…Any measures to slow down the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to decrease disease severity are highly requested. …”
-
16465
-
16466
Low efficiency induction of neural rosette-like cells from the hESCs CHA13 and CHA15 using a previously published stromal cell co-culture method.
Published 2015“…(B-E) Morphology of H9 (B), HSF6 (C), CAH13 (D), and CHA15 (E) cells under neural induction (stage I) conditions (on γ-irradiated MS5 feeder layer in ITS+AA medium). H9 and HSF6 cells formed neural rosette structures with a neuroepithelial cell morphology (arrows in B and C). …”
-
16467
-
16468
-
16469
-
16470
-
16471
-
16472
-
16473
Treatment with APB5, but not APA5 attenuates pulmonary fibrosis in BLM-treated mice.
Published 2018“…<p>BLM was injected subcutaneously with a mini-osmotic pump for 7 days. APA5, APB5, and IgG as a control were injected intraperitoneally every other day from the start on Day 0 to sacrifice on Day 28. …”
-
16474
Effects of adenosine receptor-specific antagonists on responses to hypoxia at E9.5 and E12.5.
Published 2013“…<p>A and B: Specimens were treated with DPCPX, an A1AR-specific antagonist at 10 nM (A: E9.5, n = 15; B: E12.5, n = 23), SCH-58261, an A2aAR-specific antagonist at 100 nM (A: E9.5, n = 15; B: E12.5, n = 19), or vehicle (A: E9.5, n = 27; B: E12.5, n = 42) at 15 min (arrows), and exposed to hypoxia (gray boxes). …”
-
16475
-
16476
-
16477
-
16478
-
16479
-
16480